ATG + Post-transplantation cyclophosphamide
Pre-clinicalUNKNOWN 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancy
Conditions
Hematological Malignancy
Trial Timeline
Dec 1, 2022 → Dec 1, 2025
NCT ID
NCT05629260About ATG + Post-transplantation cyclophosphamide
ATG + Post-transplantation cyclophosphamide is a pre-clinical stage product being developed by Sanofi for Hematological Malignancy. The current trial status is unknown. This product is registered under clinical trial identifier NCT05629260. Target conditions include Hematological Malignancy.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05629260 | Pre-clinical | UNKNOWN |
Competing Products
20 competing products in Hematological Malignancy